{"id":222740,"date":"2024-06-25T00:00:00","date_gmt":"2024-06-25T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/life-sciences-healthcare\/report\/47041152-medtech-contrast-agents-and-radiopharmaceuticals-market\/"},"modified":"2026-04-16T11:03:03","modified_gmt":"2026-04-16T11:03:03","slug":"47042118-medtech-contrast-agents-and-radiopharmaceuticals-market-insights-united-states","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/47042118-medtech-contrast-agents-and-radiopharmaceuticals-market-insights-united-states\/","title":{"rendered":"Contrast Agents and Radiopharmaceuticals &#8211; Market Insights &#8211; United States"},"content":{"rendered":"<p>The US contrast agents and radiopharmaceutical market will see\u00a0moderate growth over the forecast period. Market growth will be driven by <span>rising <\/span><abbr title=\"Positron Emission Tomography\">PET<\/abbr> and <abbr title=\"Magnetic Resonance Imaging\">MRI<\/abbr> procedure volumes, and the expanding use of imaging agents in <abbr title=\"Contrast-Enhanced Ultrasound\">CEUS<\/abbr> and <abbr title=\"Positron Emission Tomography\">PET<\/abbr> procedures. However, the market will be somewhat limited by the continued concern over gadolinium and radiation exposure in certain modalities. Additionally, the shift toward value-based care will act as a barrier for certain procedures, favoring those that offer the highest levels of accuracy and clarity in visualization instead. Moving forward, market growth will be driven by the introduction of new contrast agents currently in development or undergoing clinical trials, along with <abbr title=\"Food and Drug Administration\">FDA<\/abbr> approvals for expanded indications of existing contrast agents.<\/p>\n<p>This Medtech 360 Report provides comprehensive data and analysis on the state of the market for contrast agents and radiopharmaceuticals in the US from 2019 through 2033.<\/p>\n<p><strong>There has been a gradual increase in the number <abbr title=\"Food and Drug Administration\">FDA<\/abbr> approvals for <abbr title=\"Prostate-Specific Membrane Antigen\">PSMA<\/abbr> <abbr title=\"Positron Emission Tomography\">PET<\/abbr> imaging agents.<\/strong><\/p>\n<p>Which <abbr title=\"Positron Emission Tomography\">PET<\/abbr> imaging agents have received <abbr title=\"Food and Drug Administration\">FDA<\/abbr> approval?<\/p>\n<p>What advantages do these <abbr title=\"Prostate-Specific Membrane Antigen\">PSMA<\/abbr> <abbr title=\"Positron Emission Tomography\">PET<\/abbr> imaging agents offer?<\/p>\n<p>What indications are they approved for?<\/p>\n<p><strong>Manufacturers are actively engaging in ongoing clinical evaluation of their contrast agent products. <\/strong><\/p>\n<p>Which contrast agent products are under clinical evaluation?<\/p>\n<p>What advantage do they offer over the existing contrast agents in the market.<\/p>\n<p class=\"question-statement\"><strong>The <abbr title=\"Food and Drug Administration\">FDA<\/abbr> expanded approval for the use of <abbr title=\"Contrast-Enhanced Ultrasound\">CEUS<\/abbr> in radiology procedures.<\/strong><\/p>\n<p>What type of procedures does this approval extend to? What additional procedures could be approved in the future?<\/p>\n<p>Which contrast agents have received <abbr title=\"Food and Drug Administration\">FDA<\/abbr> approval?<\/p>\n<p>How will these <abbr title=\"Food and Drug Administration\">FDA<\/abbr> approvals change the competitive landscape.<\/p>\n<p class=\"question-statement\"><b>Looming concerns over the effects of gadolinium retention will negatively affect the use of contrast-enhanced <abbr title=\"Magnetic Resonance Imaging\">MRI<\/abbr>.<\/b><\/p>\n<p>How are <abbr title=\"Accountable Care Organization\">ACO<\/abbr>s, health networks, and physicians responding to the recent findings on gadolinium retention?<\/p>\n<p>What are the key differences between linear and macrocyclic <abbr title=\"Gadolinium-Based Contrast Agent\">GBCA<\/abbr>s, and how will market demand for these products shift going forward?<\/p>\n<p>Will other imaging modalities cannibalize contrast-enhanced <abbr title=\"Magnetic Resonance Imaging\">MRI<\/abbr> procedures?<\/p>\n<p>Which companies (and associated products) will benefit from the shift to macrocyclic <abbr title=\"Gadolinium-Based Contrast Agent\">GBCA<\/abbr>s?<\/p>\n","protected":false},"template":"","class_list":["post-222740","report","type-report","status-publish","hentry","report-gateway-medtech","medtech-therapy-area-contrast-agents-and-radiopharmaceuticals","medtech-therapy-area-imaging","medtech-geography-united-states","medtech-date-983"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/222740","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/222740\/revisions"}],"predecessor-version":[{"id":294237,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/222740\/revisions\/294237"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=222740"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}